Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 9.

Worm, S W; Kamara, D A; Reiss, P; Fontas, E; De Wit, S; El-Sadr, W; D'Arminio Monforte, A; Law, M; Phillips, A; Ryom, L; Dabis, F; Weber, R; Sabin, C; Lundgren, J D (2012). Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. Journal of Infectious Diseases, 205(4):535-539.

Arenas-Pinto, A; Grant, A; Bhaskaran, K; Copas, A; Carr, A; Worm, S W; Martinez, E; Reiss, P; Dunn, D; Weber, R; Hoy, J; Weller, I (2011). Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis. Antiviral Therapy, 16(2):219-226.

Smith, C J; Sabin, C A; Lundgren, J D; Thiebaut, R; Weber, R; Law, M; D'Arminio Monforte, A; Kirk, O; Friis-Moller, N; Phillips, A; Reiss, P; El-Sadr, W; Pradier, C; Worm, S W (2010). Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS, 24(10):1537-1548.

Weber, R; Sabin, C; Reiss, P; De Wit, S; Worm, S W; Law, M; Dabis, F; D'Arminio Monforte, A; Fontas, E; El-Sadr, W; Kirk, O; Rickenbach, M; Phillips, A; Ledergerber, B; Lundgren, J (2010). HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D cohort study. Antiviral Therapy, 15(8):1077-1086.

Friis-Møller, N; Thiebaut, R; Reiss, P; Weber, R; Monforte, A D; De Wit, S; El-Sadr, W; Fontas, E; Worm, S W; Kirk, O; Phillips, A; Sabin, C A; Lundgren, J D; Law, M G (2010). Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. European Journal of Cardiovascular Prevention and Rehabilitation, 17(5):491-501.

Worm, S W; Sabin, C; Weber, R; Reiss, P; El-Sadr, W; Dabis, F; De Wit, S; Law, M; D'Arminio Monforte, A; Friis-Møller, N; Kirk, O; Fontas, E; Weller, I; Phillips, A; Lundgren, J (2010). Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Journal of Infectious Diseases, 201(3):318-330.

Worm, S W; De Wit, S; Weber, R; Sabin, C A; Reiss, P; El-Sadr, W; Monforte, A D; Kirk, O; Fontas, E; Dabis, F; Law, M G; Lundgren, J D; Friis-Møller, N (2009). Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation, 119(6):805-811.

De Wit, S; Sabin, C A; Weber, R; Worm, S W; Reiss, P; Cazanave, C; El-Sadr, W; D'Arminio Monforte, A; Fontas, E; Law, M G; Friis-Møller, N; Phillips, A (2008). Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care, 31(6):1224-1229.

Sabin, C A; Worm, S W; Weber, R; Reiss, P; El-Sadr, W; Dabis, F; De Wit, S; Law, M; D'Arminio Monforte, A; Friis-Møller, N; Kirk, O; Pradier, C; Weller, I; Phillips, A N; Lundgren, J D; D:A:D Study Group (2008). Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, 371(9622):1417-1426.

This list was generated on Thu Dec 14 00:16:58 2017 CET.